PYXS today
$1.53-$0.05 (-3.16%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourDescending Triangle
15 minSymmetric Triangle
5 minDescending Triangle
Daily trend turns up above $5.55
Key levels
Resistance$1.99
Resistance$1.79
Support$1.50
Support$1.26
Latest news & SEC filings
AnalystRBC Capital Markets keeps Outperform rating on Pyxis Oncology, lifts price target
SEC FilingPyxis Oncology, Inc. filed an insider trading report (Form 4)
AnalystRBC Capital keeps Outperform rating on Pyxis Oncology, lifts target to $7
AnalystWedbush keeps Outperform rating on Pyxis Oncology, cuts price target to $7
All PYXS news →About Pyxis Oncology
Pyxis Oncology is a clinical-stage oncology company creating therapies for solid tumors, concentrating first on cancers of the head and neck. Its main candidate, micvotabart pelidotin, is an antibody-drug conjugate aimed at a fibronectin variant present in the tumor microenvironment. The company is studying this candidate alone and alongside pembrolizumab in trials conducted in the United States, Europe, and other regions.
Based on the company's 10-K filed Mar 23, 2026.
Nasdaq · Healthcare
Pyxis Oncology, Inc. (PYXS)
What Is the Price Target for PYXS?
SEPT Low Target
$7.00
SEPT Mid Target
$7.00
SEPT High Target
$12.00
Analyst Consensus
$7.00
Is PYXS a Buy or Sell Right Now?
Thesis
- •Revenue growing -14.2% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PYXS.
Start Free Trial →Is PYXS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$5.55
7
Moat Score
NONE
2/9
Piotroski Score
-7.4
Altman Z-Score
What Is Smart Money Doing with PYXS?
Insider Signal
NEUTRAL
0 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PYXS Growth Story
Revenue YoY
-14.2%
3yr Revenue CAGR
N/A%
EPS Growth YoY
3.03%
FCF Growth YoY
-9.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for PYXS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PYXS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:35:00 | $1.53 | 2,883 | $$4K | SELL |
| 16:13:57 | $1.52 | 9,000 | $$14K | BUY |
| 15:18:04 | $1.54 | 2,000 | $$3K | SELL |
| 15:05:17 | $1.53 | 5,645 | $$9K | SELL |
| 15:05:17 | $1.53 | 3,097 | $$5K | SELL |
5 dark pool trades shown · $$35K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Pyxis Oncology, Inc. (PYXS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PYXS — frequently asked questions
What is PYXS stock price today?
Pyxis Oncology, Inc. (PYXS) is at $1.53, down 3.16% (-$0.05) at the Nov 13, 2026 close.
Why is PYXS stock moving today?
Latest PYXS news — Nov 7, 2026: RBC Capital Markets keeps Outperform rating on Pyxis Oncology, lifts price target · Nov 6, 2026: Pyxis Oncology, Inc. filed an insider trading report (Form 4)
Why did PYXS stock move on Oct 27, 2026?
Pyxis Oncology shares closed at $1.84, up 8.24% on volume of 1,171,380, after the company announced that micvotabart pelidotin (MICVO) data will be featured in a late-breaking oral presentation at the EORTC-NCI-AACR Symposium. The presentation will cover MICVO monotherapy results in patients with previously treated recurrent or metastatic head and neck cancer, though the company did not disclose the actual study results in the announcement.
What is the PYXS price target?
The average analyst price target for PYXS is $7.00, ranging from $7 to $12, based on 5 analysts. Latest: Wedbush maintains on Nov 6, 2026.
What do analysts rate PYXS?
Analyst ratings for PYXS: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did PYXS beat earnings?
PYXS last reported on Nov 5, 2026: EPS -$0.24 vs -$0.29 expected — a beat of 17.2%.
Does PYXS pay a dividend?
PYXS does not currently pay a dividend.
What are PYXS support and resistance levels?
Support: $1.50, $1.26, $1.03. Resistance: $1.79, $1.99, $2.18.
What are insiders doing with PYXS?
Insider activity: NEUTRAL, 0 buys and 3 sells in the last 90 days.
What is the latest news on PYXS?
Nov 7, 2026: RBC Capital Markets keeps Outperform rating on Pyxis Oncology, lifts price target · Nov 6, 2026: Pyxis Oncology, Inc. filed an insider trading report (Form 4) · Nov 6, 2026: RBC Capital keeps Outperform rating on Pyxis Oncology, lifts target to $7